Can a sedative be safer for ICU patients with kidney issues?
NCT ID NCT06153498
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial investigates how the sedative remimazolam is processed in the bodies of ICU patients with impaired kidney function who need mechanical ventilation. It compares drug levels and safety between patients with normal and reduced kidney function. The goal is to understand if dosing adjustments are needed to achieve safe and effective sedation in this vulnerable group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remimazolam besylate (an intravenous sedative)
- What this could lead to
- If successful, this could help doctors choose safer sedation doses for ICU patients with kidney problems, reducing risks during mechanical ventilation.
- What could go wrong
- This is a small, early-stage study (36 patients) focused on drug levels and safety, not on proving clinical benefit. Kidney impairment may alter drug effects unpredictably, and results may not apply to all ICU patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MECHANICALLY VENTILATED PATIENTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wuhan Union Hospital
Wuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.